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Recent studies suggest a role of cutaneous human papillomaviruses (HPV) in non-melanoma skin cancer (NMSC)
development. In this study viral DNA loads of six frequent HPV types were determined by quantitative, type-specific
real-time-PCR (Q-PCR) in actinic keratoses (AK, n¼ 26), NMSC (n¼ 31), perilesional tissue (n¼ 22), and metastases
of squamous cell carcinomas (SCC) (n¼ 8) which were previously shown to be positive for HPV5, 8, 15, 20, 24, or 36.
HPV-DNA loads in AK, (partially microdissected) NMSC, and perilesional skin ranged between one HPV-DNA copy
per 0.02 and 14,200 cell equivalents (median: 1 HPV-DNA copy per 344 cell equivalents; n¼ 48). In 32 of the 79 HPV-
positive skin biopsies and in seven of the eight metastases viral loads were even below the detection limit of Q-
PCR. Low viral loads in NMSC were conﬁrmed by in situ-hybridization showing only a few HPV-DNA-positive nuclei
per section. Viral loads in SCC, basal cell carcinomas, and perilesional tissue were similar. But, viral loads found in
AK were significantly higher than in SCC (p¼ 0.035). Our data suggest that persistence of HPV is not necessary for
the maintenance of the malignant phenotype of individual NMSC cells. Although a passenger state cannot be
excluded, the data are compatible with a carcinogenic role of HPV in early steps of tumor development.
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Non-melanoma skin cancers (NMSC), which comprise ba-
sal cell carcinomas (BCC), squamous cell carcinomas
(SCC), and Bowen’s disease (BD), represent the most com-
mon human cancers in fair-skinned populations (Alam and
Ratner, 2001). NMSC mainly occur on sun-exposed sites
and UV radiation has been recognized as the main risk fac-
tor for NMSC development. Immunosuppressed organ
transplant recipients have a greatly increased risk of mul-
tiple and aggressive NMSC, especially SCC, indicating a
crucial role for the immune system in SCC prevention (Berg
and Otley, 2002; Euvrard et al, 2003).
Recent studies suggest an association of NMSC devel-
opment and human papillomaviruses (HPV) (for a review,
see Harwood and Proby, 2002; Pfister, 2003), whose onc-
ogenic potential is fully accepted for genital cancer (Bosch
et al, 2002; zur Hausen, 2002). The involvement of cutane-
ous HPV in human skin cancer has first been demonstrated
in patients with the rare hereditary disease epidermodyspl-
asia verruciformis (EV) (reviewed in Pfister and ter Scheg-
get, 1997). Seroepidemiology has further established a
linkage between NMSC and HPV (Feltkamp et al, 2003;
Masini et al, 2003). HPV-DNA was detected in about 20%–
50% of BCC and 30%–60% of SCC from immunocompe-
tent patients (Pfister and ter Schegget, 1997; Harwood and
Proby, 2002; Pfister, 2003). The highest prevalence was
shown with up to 93% in actinic keratoses (AK), the pre-
cursor lesions of SCC (Forslund et al, 2003b; Pfister et al,
2003). In immunosuppressed patients HPV-DNA prevalence
is even higher, sometimes reaching 100% (Pfister, 2003).
Some light was shed on the high prevalence of HPV in skin
tumors by Forslund et al (2004), who showed that removal
of the outer stratum corneum layers by tape stripping led to
a significant reduction of HPV positivity.
HPV-DNA detection usually requires nested PCR proto-
cols implying low HPV-DNA copy numbers in NMSC sam-
ples. To verify this, we developed quantitative real-time PCR
(Q-PCR) protocols for six frequent HPV types. The goal of
this study was to measure viral loads in NMSC, AK, and
perilesional tissue with special attention to different HPV-
DNA loads in premalignant (AK) and malignant (BCC, SCC)
tumors. To our knowledge, we are the first to show viral load
differences between AK and SCC. Furthermore, we were
able to localize viral DNA in NMSC by in situ-hybridization
(ISH).
Results
HPV-DNA load in biopsies For the determination of viral
DNA loads of six cutaneous EV-HPV-types (HPV5, 8, 15, 20,
Abbreviations: AK, actinic keratoses; BCC, basal cell carcinoma;
EV, epidermodysplasia verruciformis; HPV, human papillomavirus;
ISH, in situ-hybridization; NMSC, non-melanoma skin cancer; Q-
PCR, quantitative real-time PCR; RT, room temperature; SCC,
squamous cell carcinoma; TSA, tyramide signal amplification
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24, 36) 57 lesional skin biopsies, 22 samples of perilesional
skin, and eight SCC metastases were available. In 39 of
these samples HPV-DNA load was below the detection limit
of quantitative PCR (six AK, seven BCC, one BD, 10 SCC,
eight perilesional samples, seven metastases). Nine of
these (one AK, one BCC, four SCC, three perilesional tis-
sue) were excluded from statistical analyses because of low
cellular DNA input (o2000 b-globin gene copies per assay)
(Table I). In the 48 samples with quantifiable HPV-DNA load
viral loads ranged from 1 HPV-DNA copy per 14,200 cell
equivalents to 1 HPV-copy per 0.02 cell equivalents (50
HPV-DNA copies per 1 cell equivalent). Mean and median
HPV-DNA loads were 1 HPV-DNA copy per 1430 cell equiv-
alents and 1 HPV-DNA copy per 344 cell equivalents, re-
spectively. Viral load distribution was similar in samples that
carried only quantifiable types and in samples that carried
additional types. In almost all metastases (seven of eight)
and in about half of the BCC and SCC/BD samples viral
load was below detection limit of the quantitative PCR (Ta-
ble I). In contrast, only 20% of the AK samples were within
this category and viral loads of 1 HPV-DNA copy per less
than five cell equivalents were only observed with AK. The
HPV-DNA load difference between AK and SCC/BD was
shown to be significant (p¼0.035; Mann–Whitney U test,
two-sided).
From eight SCC microdissected malignant epithelial cells
could be analyzed (Fig 1). In seven of these HPV5-, 8-, 15-,
or 20 positive samples HPV-DNA load was below the de-
tection limit of the quantitative PCR. In one sample 1 HPV5-
DNA copy per 551 cell equivalents was observed (Fig 1).
To compare HPV-DNA loads in NMSC and perilesional
skin we analyzed 16 homologous pairs that carried the
same HPV type (six BCC; 10 SCC of which eight were mi-
crodissected). Three pairs of microdissected SCC and pe-
rilesional biopsies had to be excluded from this analysis
because of low b-globin DNA input. Load differences within
a half-log scale (i.e. 3-fold difference or lower) were defined
as being similar, larger differences were regarded as signif-
icant. Trends for load differences between tumor and pe-
rilesional skin could neither be observed for BCC nor for
SCC pairs. Of the six BCC/perilesional pairs two had higher
loads in the tumor, two had higher loads in the periIesional
tissue and two had similar loads in the tumor and the pe-
rilesional tissue. Of the five microdissected SCC/perilesio-
nal pairs included in the analysis, three fell into the category
‘‘similar viral load in tumor and perilesional tissue’’ and two
into the category ‘‘higher viral load in the tumor’’. Of the two
non-microdissected SCC/perilesional pairs one had a high-
er viral load in the tumor than in the perilesional tissue, and
the other one vice versa. In six perilesional biopsies that had
been positive for HPV15, 20, or 24 by screening PCR and
for which the corresponding NMSC had been HPV negative
or carried HPV types for which no Q-PCR was available,
HPV-DNA loads ranged between below detection limit of Q-
PCR and 1 HPV-DNA copy per 159 cell equivalents. Viral
loads in the small number of samples from immunosup-
pressed patients were comparable with the loads found in
samples of immunocompetent individuals.
Detection of HPV-DNA in skin biopsies by ISH Tissue for
ISH was available from three of the NMSC analyzed by Q-
PCR: one SCC (1 HPV15 copy per 708 cells) (Fig 2), two
BCC (1 HPV8 copy per 244 and per 455 cells), and the
respective perilesional tissues from three immunocompe-
tent patients. From each biopsy 3–12 sections were analy-
zed. A maximum of 20 HPV-positive nuclei per section
could be observed in the SCC. In most sections only one to
four positive nuclei were detected and some sections did
not show any signals (Fig 2, perilesional tissue with 1 HPV
copy per 2332 cells in Q-PCR). HPV-positive nuclei were
found both in the superficial more differentiated part of the
SCC and in the invasive part (Fig 2). The low number of
HPV-positive nuclei in NMSC of immunocompetent patients
was confirmed by the analysis of three further tumor/pe-
rilesional tissue pairs that had been positive for the HPV-
types 37 (SCC), RTRX5 (SCC) or RTRX9 (BD). In summary,
some HPV-DNA-positive nuclei could be detected in all bi-
opsies with the exception of one perilesional sample. Taking












Below detection limit b 87 32c 46 54c 20
One HPV copy per
4500 cells 13 37 15 23d 32
51–500 cells 0 21e 31 8 8
5–50 cells 0 10 8 15 28
o5 cells 0 0 0 0 12
aThe observed HPV-DNA load difference between AK and SCC/BD was shown to be significant (p¼ 0.035; Mann–Whitney U test, two-sided). p-values
for HPV-DNA load differences between the other sample groups were: AK versus BCC 0.084; AK versus perilesional skin 0.104; SCC/BD versus
perilesional 0.379; BCC versus perilesional 0.739; SCC/BD versus BCC 0.679.
bMean b-globin gene input copy numbers per reaction were 10280, 5914, 8712, 3242, 37724 in metastases, perilesional skin, BCC, SCC/BD, and AK,
respectively. Nine samples (one BCC, four SCC (three of which were microdissected), one AK, three perilesional (microdissected) skin biopsies) were
excluded from analysis because of low cellular DNA input (o 2000 b-globin gene copies/assay).
cTen samples were microdissected (five SCC and five perilesional biopsies): including three microdissected perilesional samples and four micro-
dissected SCC, respectively.
dIncluding one microdissected SCC.
eIncluding two microdissected perilesional samples.
BCC, basal cell carcinoma; SCC, squamous cell carcinoma; BD, Bowen’s disease; AK, actinic keratosis; HPV, human papillomavirus.
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into account the proportion of epithelial cells per section,
detection rates by ISH were similar for NMSC and periles-
ional skin in all samples analyzed.
Discussion
Early analyses of skin tumors by Southern blot hybridiza-
tion, sensitive enough to detect one HPV genome per cell,
very rarely demonstrated viral sequences (Kawashima et al,
1990), indicating low viral loads in tumors only positive in
highly sensitive PCR assays. We developed sensitive, type-
specific real-time PCR protocols for six frequent EV-asso-
ciated HPV-types and found very low viral loads in 25 AK,
13 SCC/BD, and 13 BCC. HPV-DNA loads of individual HPV
types were similar (data not shown). Forslund et al (2003a)
have analyzed HPV-DNA loads of six HPV92-positive
tumors, two AK, two SCC, and two BCC. The reported vi-
ral loads for AK and SCC are in line with our results. In
contrast, one and 94 HPV-copies per cell were found in two
BCC. We never observed loads higher than 1 HPV-DNA
copy per 21 cell equivalents in 13 BCC. It remains to be
established if the higher loads in the HPV92-positive BCC
reflect characteristics of HPV92 or the individual tumors.
In almost half of our tumor samples, which were all
shown to be positive for EV-HPV-DNA by nested PCR, the
amount of viral DNA was below the detection limit of real-
time PCR. Viral loads of 1 HPV-DNA copy per less than 500
cells were measured in 39% of BCC and 23% of SCC and
viral loads of 1 HPV-DNA copy per less than 50 cells were
determined in only 8% of BCC and 15% of SCC. Forslund
et al (2004) compared HPV-DNA positivity of swab samples
from the top of skin-tumors and biopsies which were tape
stripped to remove superficial layers. They found only a
small fraction of stripped BCC and SCC positive, which was
interpreted as an indication that HPV positivity frequently
merely reflects contamination of the lesion surface. Inter-
estingly, Forslund et al’s proportion of positive stripped bi-
opsies is similar to the proportion of NMSC with higher viral
loads in our study. We cannot exclude that the tumors with
very low viral loads of our study include cases of surface
contamination. In the majority of microdissected SCC the
amount of viral DNA was indeed below the detection limit of
real-time PCR. But, in one HPV-positive SCC and in two
HPV-positive BCC with only 1 HPV genome per 708–244
cells, a few positive nuclei, scattered both in the in situ and
the invasive part of the tumor, could be detected by the
highly sensitive TSA method. This ISH picture is fully com-
patible with the overall viral load, which furthermore ex-
cludes the possibility of viral DNA persistence in the
majority of tumor cells below the detection limit of ISH. In
clear contrast to cervical cancer (zur Hausen, 1996), the
presence of HPV therefore does not seem to be necessary
for the maintenance of the malignant phenotype of the in-
dividual tumor cells in NMSC. This view is also supported by
our finding of one HPV copy in more than 500 cells in only
one of eight metastases. We could not observe significant
viral load differences between SCC, BCC, and perilesional
skin. It is tempting to conclude from these data that HPV is
more a passenger than a driver in NMSC. The demonstra-
tion of HPV-DNA, however, in a varying fraction of NMSC
tumor cells may have an impact on growth and invasion
properties of the tumor as a whole, if the virus would trig-
ger, for example, the secretion of cytokines or metal-
loproteinases. Our study revealed significantly higher viral
loads in AK, which are the precursor lesions of SCC, than in
SCC. Viral loads of 1 HPV-DNA copy per less than 50 cells
were measured in 40% of AK. The higher viral loads in AK
Figure 1
Microdissection of tumorous and perilesional areas of a squamous
cell carcinoma (SCC). The black lines demarcate the microdissected
epithelial areas. T, tumorous/invasive area; p, perilesional area. The
SCC had 1 HPV5 copy per 551 cells in the microdissected area as
determined by quantitative real-time PCR. The viral load of the corre-
sponding microdissected perilesional tissue (normal epidermis) was 1
HPV5 copy per 71 cells.
Figure2
Human papillomavirus (HPV)-DNA detection in cryosections from
skin biopsies by in situ hybridization. HPV-DNA positive nuclei (ar-
rows) appear red (AEC staining; original magnification 100 and 400-
fold). HPV8 (a) or HPV15 (b–e) specific DNA probes were used. (a) Skin
tumor of an HPV8-transgenic mouse with 27 copies of a 5111 bp HPV8
genome fragment per cell (positive control). (b) Detail of an HPV15-
positive squamous cell carcinoma (SCC) (viral load as measured by
quantitative real-time PCR (Q-PCR) was 1 HPV15 copy per 708 cells).
(c) Homologous perilesional tissue without detectable HPV-signals (vi-
ral load as measured by Q-PCR was 1 HPV15 copy per 2332 cells). (d)
Invasive part of the same HPV15-positive SCC shown in b. The framed
rectangle is magnified in (e).
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are likely to reflect enhanced HPV-DNA replication. This
may be because of intense keratinocyte proliferation and
differentiation in AK favoring amplification of commensalic
HPV. Active HPV replication and presumably enhanced
gene expression may in turn stimulate keratinocyte prolif-
eration and contribute to carcinogenesis in these early
stages of NMSC development. HPV-E6 proteins were re-
cently shown to inhibit UV-induced apoptosis by abrogation
of Bak in response to UV damage (Jackson and Storey,
2000) and to bind a protein required for repair of single
strand DNA breaks (Iftner et al, 2002). Thereby, accumula-
tion of UV-induced mutations and oncogenic transformation
might be facilitated in cases of active HPV infection.
Material and Methods
Patient materials By screening 363 skin biopsies from recent in-
vestigations, 87 biopsies could be identified as positive for the HPV
types 5, 8, 15, 20, 24, or 36 (Wieland et al, 2000a; Pfister et al,
2003; Nindl et al, unpublished; Purdy et al, unpublished). Additional
HPV types were found in 28 biopsies. Samples comprised 26 AK,
three BD biopsies, 14 SCC, eight metastases of SCC, 14 BCC, and
22 biopsies from perilesional skin. Perilesional skin was collected
from areas directly flanking the tumors. Eight pairs of SCC biopsies
and perilesional skin consisted of microdissected invasive tumor
area and adjacent epidermal cells, respectively (Fig 1). With the
exception of the lesional–perilesional sample pairs and one patient
of whom two BCC were obtained, only one sample per patient was
analyzed. Patients’ (58% male, 42% female) mean age was 69.9 y,
ranging between 44 and 86 y. Patients had attended the Derma-
tology Departments of the Universities of either Warsaw, Berlin,
Cologne, or London. Of the 87 samples, 43 were from German, 28
from Polish and 16 (the eight pairs of microdissected SCC/pe-
rilesional tissue) from British patients. The majority of samples
(n¼ 68) had been collected from immunocompetent patients. Only
one BCC, five SCC, 10 perilesional skin biopsies and three SCC
metastases were collected from immunosuppressed transplant
recipients. The study was conducted according to Declaration of
Helsinki Principles.
Real-time PCR Type-specific Q-PCR protocols for the cutaneous
EV-associated HPV-types 5, 8, 15, 20, 24, and 36 were developed
on the LightCycler system (Roche, Mannheim, Germany) and per-
formed and evaluated as previously described (Wieland et al,
2000b; Weissenborn et al, 2003). Analytical sensitivity was two
HPV-DNA copies per reaction when duplicate testing was per-
formed. Binding sites of type specific primers and probes were
located within the L1 genes. Type-specificity was shown for all
protocols as described before (Weissenborn et al, 2003). The sup-
plemental material provides primer and probe sequences, anneal-
ing temperatures, magnesium chloride concentrations, and cycling
conditions (Table S1). To correct for PCR efficiency and DNA in-
tegrity and to determine the number of input cell equivalents, the
single-copy gene b-globin was quantified using the ‘‘LightCycler-
Control Kit DNA’’ (Roche) (Weissenborn et al, 2003). Because of the
small HPV-DNA copy numbers found, HPV-DNA loads were de-
fined as 1 HPV-DNA copy per x cell equivalents. Two b-globin-
gene copies were taken as a cell equivalent. For statistical analysis
(SPSS 10.0.7, SPSS, Illinois) HPV-DNA loads were categorized as
specified in Table I and the number of samples falling into the five
viral load categories were used as input. Each sample was quan-
tified in duplicate (mean of the relative coefficient of variation
25.7%) and mean values were used as results. Two negative con-
trols (human placental DNA) were included in each run and never
yielded fluorescence signals above background.
ISH with tyramide signal ampliﬁcation (TSA) Cryosections (5
mm) were prepared from 12 fresh frozen HPV-positive skin biopsies
(six NMSC and six homologous perilesional tissues) from immuno-
competent patients (Wieland et al, 2000a and unpublished). Ac-
cording to previous typing results, complete biotin labelled
genomic HPV plasmid DNA (HPV8, 15, or 37) or PCR-generated
420 bp L1-gene DNA fragments (RTRX5, RTRX9; Berkhout et al,
1995; Bens et al, 1998) were used as probes. ISH was performed
under high stringency conditions (Tm17.51C). Experimental de-
tails are published online as supplemental material. As positive
control (Fig 2a) skin tumor sections of an HPV8-transgenic mouse
were used which carried 27 copies of a 5111 bp HPV8 genome
fragment per cell (Schaper et al, 2005). This corresponds to 18
complete HPV8 genome (7654 nt) copies per cell. As we detected
strong signals in almost all nuclei, the sensitivity can be regarded
as high. Type specificity of the hybridization was shown by a lack of
signals using an HPV15 probe instead of an HPV8 probe.
Microdissection Formalin-fixed paraffin-embedded skin biopsies
that had been histologically confirmed as SCC were manually dis-
sected into perilesional and invasive tumor components under mi-
croscopic control. Sections (5 mm) were cut onto glass slides, one
of which was deparaffinized and stained with hematoxylin and eo-
sin. Using this section as a reference, separate sterile disposable
scalpels were used to scrape perilesional and tumor epidermal
tissue into sterile tubes. Dissections were performed in a class 2
cabinet which was UV irradiated after every sample as a precaution
against contamination.
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